NASDAQ:CARM Carisma Therapeutics (CARM) Stock Price, News & Analysis → 25% of Americans Are In Grave Danger (From Banyan Hill Publishing) (Ad) Free CARM Stock Alerts $1.08 -0.03 (-2.70%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.07▼$1.1550-Day Range$1.11▼$2.2752-Week Range$1.07▼$9.77Volume132,160 shsAverage Volume185,105 shsMarket Capitalization$44.86 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Carisma Therapeutics alerts: Email Address Carisma Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside733.3% Upside$9.00 Price TargetShort InterestHealthy7.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.72) to ($1.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.14 out of 5 starsMedical Sector460th out of 904 stocksPharmaceutical Preparations Industry215th out of 429 stocks 3.5 Analyst's Opinion Consensus RatingCarisma Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCarisma Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Carisma Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.78% of the float of Carisma Therapeutics has been sold short.Short Interest Ratio / Days to CoverCarisma Therapeutics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Carisma Therapeutics has recently decreased by 13.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCarisma Therapeutics does not currently pay a dividend.Dividend GrowthCarisma Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CARM. Previous Next 2.5 News and Social Media Coverage News SentimentCarisma Therapeutics has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Carisma Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CARM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Carisma Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.72) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Carisma Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Carisma Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCarisma Therapeutics has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Carisma Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY About Carisma Therapeutics Stock (NASDAQ:CARM)Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Read More CARM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARM Stock News HeadlinesJune 3, 2024 | americanbankingnews.comShort Interest in Carisma Therapeutics, Inc. (NASDAQ:CARM) Decreases By 13.7%May 30, 2024 | prnewswire.comCarisma Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 20, 2024 | msn.comCarisma Therapeutics Launches First Human Trial for CAR-Monocyte TherapyMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer TherapyMay 17, 2024 | markets.businessinsider.comThe Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 ExpertsMay 16, 2024 | prnewswire.comCarisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-MonocyteMay 14, 2024 | finance.yahoo.comIs There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?May 13, 2024 | msn.comCarisma Therapeutics Showcases Breakthrough in Liver and Lung Fibrosis TreatmentMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Carisma Therapeutics Amid Promising Cancer Treatment DevelopmentsMay 10, 2024 | markets.businessinsider.comBuy Rating for Carisma Therapeutics: Innovative CAR-M Therapies Poised for Market GrowthMay 9, 2024 | finanznachrichten.deCarisma Therapeutics Inc.: Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | prnewswire.comCarisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | prnewswire.comCarisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024May 7, 2024 | msn.comCarisma Therapeutics Appoints Renowned Oncologist as Chief Medical OfficerMay 6, 2024 | prnewswire.comCarisma Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceMay 2, 2024 | prnewswire.comCarisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical OfficerApril 24, 2024 | finance.yahoo.comCarisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingApril 22, 2024 | prnewswire.comCarisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed: Promising Clinical Data and Strategic Shift Bolster Carisma Therapeutics’ OutlookApril 12, 2024 | markets.businessinsider.comPromising Future for Carisma Therapeutics’ Cancer Immunotherapy: A Buy Rating AnalysisApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed on Carisma Therapeutics Amid Promising Early Research and Pipeline PotentialApril 8, 2024 | msn.comCarisma Therapeutics Welcomes New Board Member John Hohneker Amid Company EvolutionApril 4, 2024 | seekingalpha.comWall Street Breakfast Podcast: Perma-Fix Advances In PFAS Chemical EliminationApril 3, 2024 | finance.yahoo.comCarisma Therapeutics to Present at Upcoming ConferencesApril 1, 2024 | bizjournals.comPenn spinout Carisma Therapeutics reducing workforce by 37%See More Headlines Receive CARM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/08/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CARM CUSIPN/A CIK1485003 WebN/A Phone617-444-8550Fax617-858-0911Employees107Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$12.00 Low Stock Price Target$6.00 Potential Upside/Downside+733.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,880,000.00 Net Margins-538.81% Pretax Margin-539.53% Return on Equity-215.95% Return on Assets-80.58% Debt Debt-to-Equity Ratio0.08 Current Ratio4.64 Quick Ratio4.64 Sales & Book Value Annual Sales$14.92 million Price / Sales3.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book1.64Miscellaneous Outstanding Shares41,540,000Free Float34,481,000Market Cap$44.86 million OptionableNo Data Beta1.35 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Steven Kelly (Age 59)President, CEO & Director Comp: $786.91kMr. Michael Klichinsky Ph.D. (Age 34)Pharm.D., PharmD, Co-Founder & Chief Scientific Officer Comp: $525.43kMr. Richard S. Morris CPA (Age 50)CFO, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off. Comp: $584.85kDr. Saar Gill M.D.Ph.D., Co-Founder & Chairman of Scientific Advisory BoardMr. Eric H. Siegel J.D. (Age 59)MBA, General Counsel & Corporate Secretary Ms. Terry ShieldsSenior Vice President of Human ResourcesMr. Tom Wilton (Age 50)Chief Business Officer Dr. Eugene P. Kennedy F.A.C.S. (Age 55)M.D., Chief Medical Officer Mr. Kenneth LockeSenior Vice President of Technical OperationsMore ExecutivesKey CompetitorsCytosorbentsNASDAQ:CTSOExagenNASDAQ:XGNAspira Women's HealthNASDAQ:AWHLifeVantageNASDAQ:LFVNAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 11,200 shares on 5/10/2024Ownership: 3.803%Empowered Funds LLCSold 21,150 shares on 5/7/2024Ownership: 0.065%View All Institutional Transactions CARM Stock Analysis - Frequently Asked Questions Should I buy or sell Carisma Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CARM shares. View CARM analyst ratings or view top-rated stocks. What is Carisma Therapeutics' stock price target for 2024? 4 analysts have issued twelve-month target prices for Carisma Therapeutics' stock. Their CARM share price targets range from $6.00 to $12.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price. View analysts price targets for CARM or view top-rated stocks among Wall Street analysts. How have CARM shares performed in 2024? Carisma Therapeutics' stock was trading at $2.93 at the beginning of the year. Since then, CARM stock has decreased by 63.1% and is now trading at $1.08. View the best growth stocks for 2024 here. Are investors shorting Carisma Therapeutics? Carisma Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 1,570,000 shares, a decline of 13.7% from the April 30th total of 1,820,000 shares. Based on an average daily volume of 174,500 shares, the days-to-cover ratio is presently 9.0 days. Currently, 7.8% of the company's stock are sold short. View Carisma Therapeutics' Short Interest. When is Carisma Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CARM earnings forecast. How were Carisma Therapeutics' earnings last quarter? Carisma Therapeutics, Inc. (NASDAQ:CARM) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.09. The firm earned $3.40 million during the quarter, compared to the consensus estimate of $3.90 million. Carisma Therapeutics had a negative net margin of 538.81% and a negative trailing twelve-month return on equity of 215.95%. Who are Carisma Therapeutics' major shareholders? Carisma Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.80%), Empowered Funds LLC (0.06%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Carisma Therapeutics? Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CARM) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.